SUBSCRIBE
SUBSCRIBE
News   FDA

Novartis AG Sight Drug Gets Broader EU Approval

January 7, 2011 | 
1 min read
ZURICH, Jan 7 (Reuters) - Swiss drugmaker Novartis AG (NOVN.VX) said on Friday the European Commission has approved broader application of its Lucentis drug to treat visually impaired patients, giving sales of the drug a potential boost.
FDA Approvals Europe
Novartis
MORE ON THIS TOPIC
Wooden blocks with arrow and error icon. Delays and disruptions, stop the process, critical error concept
Neurodegenerative disease
Edgewise Takes a Hit as FDA Blocks Accelerated Path for Becker Muscular Dystrophy Drug
June 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Successful businessman standing in front of multiple pathways, making a decision for the right move. A symbol of great investment and positive progress in the development of business. stock illustration
Mergers & acquisitions
Lilly-Verve Proxy Filing Reveals Tumult After Departure of FDA’s Marks
June 26, 2025
 · 
4 min read
 · 
Annalee Armstrong
FDA Headquarters_Grandbrothers/Adobe Stock
Policy
Former CBER Chief Marks Decries New FDA COVID-19 Framework
June 26, 2025
 · 
3 min read
 · 
Tristan Manalac
Finding Talent. Big Hands with Magnifying Glass Recruiting People. vector
Duchenne muscular dystrophy
FDA Reviews Sarepta’s Elevidys After Second Patient Death
June 25, 2025
 · 
2 min read
 · 
Tristan Manalac